Cabozantinib is a c-Met inhibitor that is currently FDA approved for the treatment of patients with advanced renal cell carcinoma (RCC).
| SparkCures ID | 69 |
|---|---|
| Developed By | Exelixis |
| Generic Name | Cabozantinib |
| Additional Names | Cabometyx |
| Treatment Classifications |
View all active clinical trials around the US.
There are no resources, links or videos to display for this treatment.